Multimodally trackable and clinically translatable platform for modelling human demyelinating brain diseases by temporally dispersed chemically induced lesions in the pig brain

Mihai Ancău, Goutam Kumar Tanti, Vicki M. Butenschöen, Jens Gempt, Igor Yakushev, Stephan G. Nekolla, Mark Mühlau, Christian Scheunemann, S. Heininger, Benjamin Löwe, Erik Löwe, Silke Baer, Johannes Fischer, Judith Reiser, Sai S. Ayachit, Friederike Liesche‐Starnecker, Jürgen Schlegel, Kaspar Matiasek, Martina Schifferer, Jan S. Kirschke, Thomas Misgeld, Tim C. Lueth, Bernhard HemmerbioRxiv 2023 · DOI

TL;DR

This paper introduces "MiniSWINE," a novel platform using minipigs to model human demyelinating brain diseases like Multiple Sclerosis (MS). By inducing controlled lesions and using human-compatible imaging techniques (MRI, PET) and electron microscopy, MiniSWINE offers a more translatable model than rodents, paving the way for better diagnostic tools and therapeutic testing.

What Problem Does This Paper Address?

Inflammatory demyelinating diseases, such as Multiple Sclerosis (MS), are a major cause of disability. While rodent models have been crucial for understanding these diseases, their small brain size and limited white matter content make it difficult to apply human diagnostic imaging techniques. This translational gap hinders the development and testing of new therapies. Large animal models offer better anatomical similarity to humans, but developing precise and trackable methods for inducing and studying lesions in these models has been challenging.

Methods

The core of this work is the MiniSWINE (Minipig Stereotactic White-matter Injection using Navigation by Electromagnetism) platform. Key methodological innovations include:

  • Controlled Demyelination: Lysophosphatidylcholine (LPC) was injected into the minipig brain to induce reversible, targeted demyelinating lesions. Serial induction allowed for studying different stages of de- and remyelination in parallel.
  • Electromagnetic Tracking System (EMTS): A novel EMTS was developed for precise, real-time tracking of the injection cannula tip. This system overcomes limitations of optical tracking, particularly in challenging surgical environments.
  • Minipig Model: Minipigs were chosen for their relatively large, gyrencephalic brains, anatomical similarity to humans, and manageable size for stereotactic procedures.
  • Multimodal Imaging: The induced lesions were tracked using standard clinical imaging modalities: 3T MRI (including T2FLAIR, T1Gd, SWI, DIR, MPRAGE sequences) and ¹¹C-PIB PET.
  • Histopathology and Electron Microscopy: Standard histopathology and advanced electron microscopy were used to characterize the lesions and compare them with biopsy data from human patients with demyelinating diseases.

Datasets

  • Minipig Brain Lesions: The study generated data from induced demyelinating lesions in minipigs at acute, intermediate, and subacute stages.
  • Human Brain Biopsies: Biopsy data from two human patients (one with acute MS, one with subacute ADEM) were used for comparison.

Key Insights and Ideas

  • Bridging the Translational Gap: MiniSWINE successfully bridges the gap between rodent models and human clinical studies by using a large animal model and human-compatible diagnostic tools.
  • Precise Lesion Induction: The EMTS-guided injection system allows for highly accurate and reproducible placement of lesions, crucial for controlled experimental studies.
  • Divergent Remyelination Dynamics: The remyelination process observed in minipigs differs from classical rodent models, showing incomplete remyelination at the subacute stage and persistent inflammatory markers, which more closely mirrors human disease.
  • Clinical Imaging Validation: The study demonstrates that standard clinical MRI and PET sequences can effectively track de- and remyelination in this large animal model, validating its potential for developing new imaging biomarkers.

Key Results

  • Controlled Demyelination: LPC injection successfully induced reversible, clinically unapparent demyelinating lesions in the minipig white matter.
  • Multimodal Tracking: Lesions were successfully tracked over time using MRI and PET, showing changes consistent with de- and remyelination.
  • Histopathological Correlation: Histological and electron microscopy analyses confirmed demyelination and remyelination processes, aligning with imaging findings.
  • Human Model Comparison: Ultrastructural analysis of minipig lesions showed strong similarities to human MS and ADEM lesions, particularly in axonal diameter and g-ratios.
  • Remyelination Differences: Minipig remyelination was characterized by incomplete myelin restoration and persistent astroglial/microglial activation, unlike the more complete remyelination seen in rodent models.

Limitations and Future Work

  • Interference with EMTS: The EMTS experienced some interference with metallic surgical instruments, requiring careful management.
  • Limited Human Data: The comparison with human biopsies was limited by the availability of samples from different brain regions and disease stages.
  • Subacute Stage Sample Size: The number of lesions analyzed at the subacute stage was smaller due to the sequential nature of the experiments.
  • Future Work: The authors suggest that MiniSWINE can be used for developing diagnostic procedures, discovering imaging biomarkers, and testing novel remyelinating agents for diseases like MS. The EMTS technology could also enhance stereotactic substance delivery in human neurosurgery.

Summary updated

Abstract

Abstract Background Despite advances in therapy, inflammatory demyelinating diseases of the central nervous system, such as multiple sclerosis, remain important causes of morbidity among young adults. Translation of remyelinating paradigms from current murine models is encumbered by the small size and low white matter content of the brains, limiting the spatial resolution of diagnostic imaging. Large animal models might be more suited for this purpose but pose significant technological, ethical and logistical challenges. Method We induced reversible and targeted cerebral demyelinating lesions by controlled injection of lysophosphatidylcholine in the minipig brain. One strength of the approach is the serial induction, allowing parallel imaging of successive stages of de-/remyelination. Findings We demonstrate controlled, clinically unapparent, reversible and multimodally trackable brain white matter demyelination in a large animal model. Lesions were amenable to follow-up using the same clinical imaging modalities (3T magnetic resonance imaging, 11 C-PIB positron emission tomography) and standard histopathology protocols as for human diagnostics, as well as electron microscopy to compare against biopsy data from two patients with cerebral demyelination. Interpretation By employing human diagnostic tools and validating the model against data from related human diseases, our platform overcomes one important translational barrier of current animal brain demyelination models while having the potential for developing diagnostic procedures and imaging biomarkers. Remyelination and axon preservation dynamics diverge from classical rodent models. Funding This work was supported by the DFG under Germany’s Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy, ID 390857198) and TRR 274/1 2020, 408885537 (projects B03 and Z01). Research in context Evidence before this study Inflammatory demyelinating diseases of the central nervous system (CNS), targeting primarily the white matter (WM) of the brain and spinal cord, such as multiple sclerosis (MS), still represent some of the most important non-traumatic causes of disability in young adults. Current animal models based on murine species, for example, experimental autoimmune encephalomyelitis, have been demonstrated to reliably depict pathophysiological facets of human disease. However, they are nevertheless encumbered by the low WM content and the small size of murine brains, which still pose a translational barrier to diagnostic imaging tools used in a clinical context in human patients. Minipigs are increasingly being used to model human neurological diseases, as yet primarily in the context of neurodegenerative disorders. Added value of this study Here, we establish a platform for Minipig Stereotactic White-matter Injection using Navigation by Electromagnetism (MiniSWINE) and validate such a tool in a clinical multimodal imaging and microscopy setting against biopsy and imaging data from human demyelinating disorders across different disease stages, as well as against existing and potentially emerging human diagnostic imaging. Moreover, in order to overcome the neuroanatomical challenges of stereotactic injection in the pig brain, we designed a new electromagnetic-guided tracking system whose key advantage is the direct measurement of the injection cannula tip position in situ. Another strength of our study lies in its setup, characterized by the serial induction of successive stages of de- and remyelination, allowing for multimodal assessment via imaging and histopathology or electron microscopy of multiple stages in parallel. The remyelination dynamics inferred in this context diverge from the classical rodent studies, by exhibiting incomplete remyelination at the subacute stage, persistent astroglial and microglial activation as well as a minor degree of secondary axonal degeneration. Thus, they more closely resemble human inflammatory demyelinating brain plaques. Implications of all the available evidence We believe that MiniSWINE links evidence from well-established demyelination-induction methods from rodent models of CNS demyelinating disorders, as well as from human imaging and biopsy data, while at the same time providing a novel platform for the potential development of diagnostic procedures, discovery of imaging biomarkers and testing of remyelinating agents in diseases such as MS. Thus, it can have particular relevance to human health in the context of future translational animal model-based research in inflammatory demyelinating disorders of the CNS. Additionally, our electromagnetic-guided injection technique may enhance stereotactic substance delivery in human neurosurgery.
BibTeX
@misc{ancau2023multimodally,
  author = {Mihai Ancău and Goutam Kumar Tanti and Vicki M. Butenschöen and Jens Gempt and Igor Yakushev and Stephan G. Nekolla and Mark Mühlau and Christian Scheunemann and S. Heininger and Benjamin Löwe and Erik Löwe and Silke Baer and Johannes Fischer and Judith Reiser and Sai S. Ayachit and Friederike Liesche‐Starnecker and Jürgen Schlegel and Kaspar Matiasek and Martina Schifferer and Jan S. Kirschke and Thomas Misgeld and Tim C. Lueth and Bernhard Hemmer},
  title = {{Multimodally trackable and clinically translatable platform for modelling human demyelinating brain diseases by temporally dispersed chemically induced lesions in the pig brain}},
  year = {2023},
  doi = {10.1101/2023.07.26.550644},
  howpublished = {bioRxiv},
}
Figure